[
    [
        {
            "time": "2018-10-30",
            "original_text": "Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View",
            "features": {
                "keywords": [
                    "Q3",
                    "Earnings",
                    "Misses",
                    "Revenues",
                    "Updates"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Pfizer Missed Analysts’ Third-Quarter Revenue Estimates",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Missed",
                    "Analysts",
                    "Third-Quarter",
                    "Revenue",
                    "Estimates"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pfizer Missed Analysts’ Third-Quarter Revenue Estimates",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance",
            "features": {
                "keywords": [
                    "Allergan",
                    "Beats",
                    "Q3",
                    "Earnings",
                    "Raises",
                    "Guidance"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Sanofi: Analysts’ Recommendations on October 30",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Analysts",
                    "Recommendations",
                    "October"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Sanofi: Analysts’ Recommendations on October 30",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Sanofi’s Q3 Estimates: Expect Revenue Growth",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Q3",
                    "Estimates",
                    "Revenue",
                    "Growth"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi’s Q3 Estimates: Expect Revenue Growth",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Your first trade for Tuesday, Oct 30",
            "features": {
                "keywords": [
                    "first",
                    "trade",
                    "Tuesday",
                    "Oct"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Your first trade for Tuesday, Oct 30",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "This is Why Eli Lilly (LLY) is a Great Dividend Stock",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "Dividend",
                    "Stock"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "This is Why Eli Lilly (LLY) is a Great Dividend Stock",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Better Buy: Celgene Corporation vs. Gilead Sciences",
            "features": {
                "keywords": [
                    "Better",
                    "Buy",
                    "Celgene",
                    "Corporation",
                    "Gilead",
                    "Sciences"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Better Buy: Celgene Corporation vs. Gilead Sciences",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Elanco Animal Health Names Todd Young CFO - Quick Facts",
            "features": {
                "keywords": [
                    "Elanco",
                    "Animal",
                    "Health",
                    "Names",
                    "Todd",
                    "Young",
                    "CFO"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "animal health"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Elanco Animal Health Names Todd Young CFO - Quick Facts",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]